Status epilepticus and tiagabine therapy: Review of safety data and epidemiologic comparisons

Epilepsia

Volumn 42, Issue 3, 2001, Pages 372-379

  Shinnar, Shlomo ^a,i   Berg, Anne T ^b   Treiman, David M ^c   Allen Hauser, W ^d   Hesdorffer, Dale C ^d   Chris Sackellares, J ^e   Leppik, Ilo ^f   Sillanpaa, Matti ^g   Sommerville, Kenneth W ^h  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NORTHERN ILLINOIS UNIVERSITY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h ABBOTT LABORATORIES   (United States)

ⁱ MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Electroencephalography; Epidemiology; GABA; Status epilepticus; Tiagabine

Indexed keywords

DIAZEPAM; LORAZEPAM; PHENYTOIN; PLACEBO; TIAGABINE;

ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; DISEASE ASSOCIATION; DRUG SAFETY; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FOCAL EPILEPSY; HIGH RISK PATIENT; HUMAN; INCIDENCE; LONG TERM CARE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPIKE WAVE;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; COHORT STUDIES; CONTROLLED CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; EPILEPSY, COMPLEX PARTIAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NIPECOTIC ACIDS; PLACEBOS; RISK FACTORS; STATUS EPILEPTICUS;

EID: 0035062533     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2001.01600.x     Document Type: Article

References (39)

1. Tiagabine
2. Tiagabine
3. Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine
4. Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram spikewave discharges and behavior of rats
5. Utility of the lethargic (1h/1h) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures
6. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984
7. Incidence of status epilepticus in Rochester, Minnesota 1965-1984
8. Long-term prognosis of seizures with onset in childhood
9. Sillanpaa M, Jalava M, Shinnar S, Status epilepticus in a population based cohort with childhood onset epilepsy in Finland
10. The risk of seizure recurrence following a first unprovoked afebrile seizure in childhood: An extended follow-up
11. Predictors of recurrent febrile seizures: A prospective study of the circumstances surrounding the initial febrile seizure
12. Complex febrile seizures
13. Predictors of recurrent feb rile seizures
14. The treatment of convulsive status epilepticus: Recommendations of the Epilepsy Foundation of America's working group on status epilepticus
15. Guidelines for epidemiological studies on epilepsy
16. Proposal for revised clinical and electroencephalographic classification of epileptic seizures
17. Proposal for revised classification of epilepsies and epileptic syndromes
18. Tiagabine for complex partial seizures: A randomized, add-on, dose-response trial
19. Tiagabine therapy for complex partial seizures: A dose- frequency study
20. Safety of tiagabine: Summary of 53 trials
21. Tiagabine monotherapy in the treatment of partial epilepsy
22. Nonconvulsive status epilepticus in adults: Thirty two consecutive patients from a general hospital population
23. A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor
24. Basic mechanisms of generalized absence seizures
25. Seizure-inducing effects of antiepileptic drugs: A review
26. Status epilepticus in children with newly diagnosed epilepsy
27. Risk factors for status epilepticus in children with symptomatic epilepsy
28. How long do seizures last in children with new-onset seizures
29. Tiagabine and non-convulsive status epilepticus
30. Non-convulsive status epilepticus in two patients receiving tiagabine treatment
31. Tiagabin und nonkonvulsiver status epilepticus
32. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy
33. Clinical and EEG findings in complex partial status epilepticus with tiagabine
34. Tiagabine-induced absence status in idiopathic generalized epilepsy
35. Treatment of generalized seizures in a long-term trial of Gabitril